Trial Profile

A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI324 in Subjects With Diabetic Macular Edema(DME)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI 324 (Primary)
Indications Diabetic macular oedema
Focus Adverse reactions; First in man
Sponsors Innovent Biologics

Most Recent Events

06 Nov 2023 Results published in the Innovent Biologics Media Release
06 Nov 2023 According to Innovent Biologics media release, data from this study presented at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting,
25 Oct 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com